Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes

Oraya Supplement: Oraya Therapy for Wet AMD, Real World Clinical Outcomes
Age-related macular degeneration (AMD) affects an estimated 30 million to 50 million people worldwide and is the leading cause of severe vision loss in higher income countries. Neovascular AMD accounts for about 10 per cent of AMD cases, but for about 90 per cent of the severe vision loss that AMD causes. It affects approximately 1.3 per cent of people over 50 years old, with approximately 600,000 new cases of neovascular AMD diagnosed annua Download Supplement - click here
Tags: ocular pathology
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...